Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Deffered Revenue: 2011-2017

Historic Non-Current Deffered Revenue for Abeona Therapeutics (ABEO) over the last 7 years, with Dec 2017 value amounting to $3.1 million.

  • Abeona Therapeutics' Non-Current Deffered Revenue fell 16.46% to $3.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $3.1 million, marking a year-over-year decrease of 16.46%. This contributed to the annual value of $3.1 million for FY2017, which is 16.46% down from last year.
  • According to the latest figures from Q4 2017, Abeona Therapeutics' Non-Current Deffered Revenue is $3.1 million, which was down 4.70% from $3.2 million recorded in Q3 2017.
  • Over the past 5 years, Abeona Therapeutics' Non-Current Deffered Revenue peaked at $5.5 million during Q2 2013, and registered a low of $2.6 million during Q1 2013.
  • Over the past 3 years, Abeona Therapeutics' median Non-Current Deffered Revenue value was $3.9 million (recorded in 2016), while the average stood at $3.9 million.
  • Per our database at Business Quant, Abeona Therapeutics' Non-Current Deffered Revenue spiked by 101.21% in 2014 and then dropped by 16.46% in 2017.
  • Over the past 5 years, Abeona Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $5.2 million in 2013, then declined by 7.12% to $4.9 million in 2014, then fell by 12.37% to $4.3 million in 2015, then fell by 14.11% to $3.7 million in 2016, then dropped by 16.46% to $3.1 million in 2017.
  • Its last three reported values are $3.1 million in Q4 2017, $3.2 million for Q3 2017, and $3.4 million during Q2 2017.